The Barmicil is a powerful compound that has great benefits and profits. Here we tell you all the details.
Index
Barmicil – Indications and use
Barmicil Compound Nasal Aerosol is a corticosteroid indicated for the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis in patients 4 years of age and older. The nasal spray is indicated for the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis in patients 4 years of age and older.
Barmicil – Dosage and administration
Administer Barmicil Compound Nasal Spray intranasally only. Barmicil Compound (Beclomethasone Dipropionate) should be primed before initial use by acting four times. To do this, remove the protective cap from the device, hold the device upright between your thumb and forefinger (index finger). The canister should be on top, pointing downward and spray 4 times in the air, away from the eyes and face. After the initial priming, the dose counter should read 120 for Compound Barmicil (Beclomethasone Dipropionate).
Nasal Spray is not used for 7 consecutive days, it must be primed by spraying 2 times. Please refer to the accompanying Patient Information Leaflet and Instructions for Use for the proper use of Barmicil Compound (Beclomethasone Dipropionate) Nasal Spray. The nasal spray is for intranasal use only.
The recommended dose of Barmicil Compound (Beclomethasone Dipropionate) is 80 mcg nasal spray in patients 12 years and older is 320 mcg per day administered as 2 actions in each nostril once a day (maximum total daily dose of 4 shares per day). The recommended dose of Barmicil Compound (Beclomethasone Dipropionate) is 40 mcg Nasal Spray in children 4 to 11 years of age and 80 mcg per day administered as 1 actuation in each nostril once a day (maximum total daily dose of 2 actions per day).
Allergic rhinitis in adults and adolescents (12 years of age and older): The recommended dose of Barmicil Compound (Beclomethasone Dipropionate) Nasal Spray is 320 mcg per day administered as 2 actions in each nostril (QNASL 80 mcg Nasal Spray) one once daily (maximum total daily dose of 4 actions per day).
Children (4-11 years of age): The recommended dose of Barmicil Compound (Beclomethasone Dipropionate) Nasal Spray is 80 mcg per day given as 1 actuation in each nostril (QNASL 40 mcg Nasal Spray) once daily ( maximum total daily dose of 2 actions per day).
Barmicil – Benefits
The nasal spray is a non-aqueous nasal spray solution. Each performance of Barmicil Compound (Beclomethasone Dipropionate) and each resistance is supplied in a 8.7 g container containing 120 performances. Barmicil Compound (Beclomethasone Dipropionate) is also supplied in a 4.9 g bottle containing 60 actuations. The nasal spray is available in two strengths: Each actuation of Compound Barmicil (Beclomethasone Dipropionate) delivers 40 mcg Compound Barmicil Dipropionate (Beclomethasone Dipropionate). Each power is supplied in a 8.7g container containing 120 actuations; Barmicil Compound (Beclomethasone Dipropionate) is also supplied in a 4.9 g bottle containing 60 actuations.
Barmicil – Contraindications
Barmicil Compound (beclomethasone dipropionate) Nasal Spray is contraindicated in patients with a history of hypersensitivity to Barmicil Compound (beclomethasone dipropionate) dipropionate and / or any other Barmicil Compound (beclomethasone dipropionate). Patients with a history of hypersensitivity to Compound Barmicil Dipropionate (Beclomethasone Dipropionate) and / or any other ingredient in Compound Barmicil Nasal Spray (Beclomethasone Dipropionate).
Barmicil – Warnings and Precautions
Nasal discomfort, epistaxis, nasal ulceration, Candida albicans infection, nasal septum perforation, impaired wound healing. Monitor patients periodically for signs of adverse effects on the nasal mucosa. Avoid use in patients with recent nasal ulcers, nasal surgery, or nasal trauma.
Eye disorders Monitor patients closely with a change in vision or a history of increased intraocular pressure, blurred vision, glaucoma, and / or cataracts. Hypersensitivity, rash and hives may occur after administration of Barmicil Compound (Beclomethasone Dipropionate) Nasal Spray.
Potential fungal, bacterial, viral or parasitic infections; or ocular herpes simplex. More serious or even deadly causes of chickenpox or measles in susceptible patients. Be careful in patients with the above due to the potential for worsening of these infections.
Hypercorticism and adrenal suppression with very high doses or in regular doses in susceptible individuals. If such changes occur, slowly discontinue Barmicil Compound (Beclomethasone Dipropionate) nasal spray. Potential reduction in growth rate in pediatric patients. Monitor growth routinely in pediatric patients receiving Barmicil Compound Nasal Spray (Beclomethasone Dipropionate).
Local Nasal Effects: Nasal discomfort, nasal epistaxis and ulceration: In clinical trials lasting 2 to 52 weeks, nasal epistaxis and ulcerations were observed more frequently and some episodes of epistaxis were more severe in patients treated with Barmicil Compound (Beclomethasone dipropionate) . In the 52-week safety trial in patients with perennial allergic rhinitis, nasal erosions were identified in 4 of 415 patients and nasal ulceration was identified in 1 of 415 patients treated with Barmicil Compound (Beclomethasone Dipropionate) Nasal Spray.
No nasal erosions or ulcerations were reported in patients receiving placebo. In clinical trials conducted in pediatric patients 4 to 11 years of age, the local nasal effect was similar to those reported in patients 12 years of age and older. Patients using Barmicil Compound (Beclomethasone Dipropionate) Nasal Spray for several months or longer should be periodically examined for possible changes in the nasal mucosa. If an adverse reaction (eg, erosion, ulceration) is observed, discontinue Barmicil Compound (Beclomethasone Dipropionate) nasal spray.
Candida infection: In previous clinical trials with an aqueous formulation of Beclomethasone dipropionate administered intranasally, localized infections of the nose and pharynx with Candida albicans have been reported. There were no cases of similar infections seen in clinical trials with Barmicil Compound (Beclomethasone Dipropionate) Nasal Spray. If such an infection develops, it may require treatment with appropriate local therapy and discontinuation of Barmicil Compound (Beclomethasone Dipropionate) nasal spray treatment. Therefore, patients using Barmicil Compound (Beclomethasone Dipropionate) Nasal Spray for several months or more should be periodically examined for signs of Candida infection.
Nasal septum perforation: Cases of nasal septum perforation have been reported in patients after intranasal application of Compound Barmicil Dipropionate (Beclomethasone Dipropionate). No nasal septum perforations were reported during clinical trials at the indicated dose of Barmicil Compound (beclomethasone dipropionate) 80 mcg nasal spray administered as 320 mcg once daily in adults and adolescents. There was one report of nasal septum perforation observed in the pediatric dose range clinical trial.
Eye disorders
The use of intranasal and inhaled corticosteroids can cause increased intraocular pressure, blurred vision, glaucoma and / or cataracts. Therefore, close monitoring is required in patients with a change in vision. Glaucoma and cataract formation were evaluated with ocular evaluations including intraocular pressure measurements and slit lamp examinations in 245 adolescent and adult patients with perennial allergic rhinitis treated with Barmicil Compound (Beclomethasone Dipropionate), nasal spray 320 mcg daily (N = 197) or placebo (N = 48) for up to 52 weeks. In 94% of patients, intraocular pressure (IOP) remained within the normal range (<21 mmHg) during the treatment portion of the trial.
Dr. Samantha Robson ( CRN: 0510146-5) is a nutritionist and website content reviewer related to her area of expertise. With a postgraduate degree in Nutrition from The University of Arizona, she is a specialist in Sports Nutrition from Oxford University and is also a member of the International Society of Sports Nutrition.
